Credit: ImmunityBio. Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist. The Food and Drug Administration (FDA) has approved Anktiva ® (nogapendekin alfa inbakicept-pmln) with ...

In a study, veterans who used TNF blockers to treat inflammatory bowel disease had an increased risk for kidney function decline. Anti-tumor necrosis factor (anti-TNF) therapy may increase the ...

Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was ...

Diabetes was linked to a significant increase in risk for shingles hospitalizations and complications, especially among men and older patients. Comorbid diabetes significantly increases ...

Compared with usual clinic-based hypertension care, telemedicine management of hypertension is more effective for improving blood pressure control. Telemedicine management of hypertension (HTN) is ...

The IMPACT-CKD analysis predicts escalating and varied burdens of CKD and its sequelae across 8 countries by 2032. Chronic kidney disease (CKD) is expected to affect 11.7% to 16.5% of the general ...

Among patients with cancer, death risks are higher for those with vs without kidney failure. Cancer survival is lower among patients with kidney failure, a recent study finds. Among the entire ...

Treating anemia in patients with CKD earlier, before hemoglobin levels fall below 9.0 g/dL, may reduce risks for cardiovascular events. Delaying renal anemia treatment with long-acting ...

Antiangiogenic drugs, crizotinib, and ICIs were associated with the development of hypogonadism in high-risk men who were treated for cancer. Hypogonadism and its management have an impact on symptom ...

Direct anti-VEGF angiogenic agents were a strong risk factor for high-grade hypertension, and multikinase inhibitors for high-grade proteinuria. Vascular endothelial growth factor signaling pathway ...

The MyProstateScore 2.0 urine test captures 17 biomarkers of clinically significant prostate cancer, independent of PSA. A positive result can rule in and a negative result can rule out the need ...